{"id":880043,"date":"2025-08-28T08:35:02","date_gmt":"2025-08-28T12:35:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"modified":"2025-08-28T08:35:02","modified_gmt":"2025-08-28T12:35:02","slug":"aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","title":{"rendered":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference"},"content":{"rendered":"
\n

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities\u00a0while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York.<\/p>\n

\n
\n Presentation Details<\/u>
\n <\/strong>\n <\/p>\n

Date\/ time: Tuesday, September 9\u00a0at\u00a03:30 PM\u00a0ET
Location: Lotte New York Palace Hotel
Webcast link:\u00a0click here<\/a><\/p>\n

The webcast will be available for 90 days at the link above or on the Aprea Investors page, under \u201cNews & Events.\u201d<\/p>\n

\n About Aprea
<\/strong>Aprea\u2019s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues, thereby reducing the risk of toxicity often associated with conventional chemotherapy and other treatments. Aprea\u2019s lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications. For more information, please visit the company website at\u00a0www.aprea.com<\/a>.<\/p>\n

The Company may use, and intends to use, its investor relations website at\u00a0https:\/\/ir.aprea.com\/<\/a>\u00a0as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.<\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities\u00a0while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date\/ time: Tuesday, September 9\u00a0at\u00a03:30 PM\u00a0ETLocation: Lotte New York Palace HotelWebcast link:\u00a0click here The webcast will be available for 90 days at the link above or on the Aprea Investors page, under \u201cNews & Events.\u201d About ApreaAprea\u2019s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell … <\/p>\n

Continue reading “Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-880043","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nAprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities\u00a0while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date\/ time: Tuesday, September 9\u00a0at\u00a03:30 PM\u00a0ETLocation: Lotte New York Palace HotelWebcast link:\u00a0click here The webcast will be available for 90 days at the link above or on the Aprea Investors page, under \u201cNews & Events.\u201d About ApreaAprea\u2019s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell … Continue reading "Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T12:35:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference\",\"datePublished\":\"2025-08-28T12:35:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"},\"wordCount\":247,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\",\"name\":\"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=\",\"datePublished\":\"2025-08-28T12:35:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk","og_description":"DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc.\u00a0(Nasdaq: APRE) (\u201cAprea\u201d, or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities\u00a0while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York. Presentation Details Date\/ time: Tuesday, September 9\u00a0at\u00a03:30 PM\u00a0ETLocation: Lotte New York Palace HotelWebcast link:\u00a0click here The webcast will be available for 90 days at the link above or on the Aprea Investors page, under \u201cNews & Events.\u201d About ApreaAprea\u2019s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell … Continue reading \"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-08-28T12:35:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference","datePublished":"2025-08-28T12:35:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"},"wordCount":247,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/","name":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=","datePublished":"2025-08-28T12:35:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTUxOTM5OSM3MTE4ODkxIzIxODEyODA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aprea-therapeutics-to-present-at-h-c-wainwright-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=880043"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/880043\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=880043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=880043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=880043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}